Adult Medulloblastoma: Updates on Current Management and Future Perspectives

Enrico Franceschi, Caterina Giannini, Julia Furtner, Kristian W. Pajtler, Sofia Asioli, Raphael Guzman, Clemens Seidel, Lidia Gatto, Peter Hau

Research output: Contribution to journalReview articlepeer-review

Abstract

Medulloblastoma (MB) is a malignant embryonal tumor of the posterior fossa belonging to the family of primitive neuro-ectodermic tumors (PNET). MB generally occurs in pediatric age, but in 14–30% of cases, it affects the adults, mostly below the age of 40, with an incidence of 0.6 per million per year, representing about 0.4–1% of tumors of the nervous system in adults. Unlike pediatric MB, robust prospective trials are scarce for the post-puberal population, due to the low incidence of MB in adolescent and young adults. Thus, current MB treatments for older patients are largely extrapolated from the pediatric experience, but the transferability and applicability of these paradigms to adults remain an open question. Adult MB is distinct from MB in children from a molecular and clinical perspective. Here, we review the management of adult MB, reporting the recent published literature focusing on the effectiveness of upfront chemotherapy, the development of targeted therapies, and the potential role of a reduced dose of radiotherapy in treating this disease.

Original languageEnglish (US)
Article number3708
JournalCancers
Volume14
Issue number15
DOIs
StatePublished - Aug 2022

Keywords

  • chemotherapy
  • medulloblastoma
  • neurosurgery
  • radiotherapy
  • SHH inhibitors
  • SHH pathway
  • sonic hedgehog (SHH)
  • sonidegib
  • targeted therapy
  • vismodegib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adult Medulloblastoma: Updates on Current Management and Future Perspectives'. Together they form a unique fingerprint.

Cite this